LONDON & BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 24, 2018-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the US Food and Drug Administration ( FDA ) has approved an expanded indication for Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol

Once-daily single inhaler triple therapy superior to Relvar/Breo Ellipta and Anoro Ellipta across multiple endpoints including exacerbations, lung function and quality of life LONDON & BRISBANE, Calif. --(BUSINESS WIRE)--Apr. 18, 2018-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc.

LONDON & BRISBANE, Calif. --(BUSINESS WIRE)--Mar. 8, 2018-- GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Commission has approved a label update for the use of once-daily Relvar Ellipta (fluticasone furoate/vilanterol, FF/VI), an inhaled

LONDON & BRISBANE, Calif. --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy Ellipta

LONDON & BRISBANE, Calif. --(BUSINESS WIRE)--Feb. 14, 2018-- GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the submission of the landmark IMPACT data to the European Medicines Agency as part of a type II variation to support an expanded label for Trelegy

Royalties earned of $70.5 million in the fourth quarter of 2017, up 51% from the fourth quarter of 2016. Royalties earned in 2017 reached $227.9 million , up 56% from 2016. Net income attributable to Innoviva stockholders of $58.4 million for the fourth quarter of 2017 (up 129% from the fourth

BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (NASDAQ: INVA) announced today that it will report financial results for the fourth quarter and year ended December 31, 2017 after market close on February 8, 2017 . Following the earnings release, Innoviva management will host a webcast and

LONDON & BRISBANE, Calif. --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/NYSE:GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending a label update for the use

Appoints George Bickerstaff , III and Odysseas Kostas , M.D. to the Board BRISBANE, Calif. --(BUSINESS WIRE)-- Innoviva, Inc. (the "Company" or " Innoviva") (NASDAQ: INVA) today announced it implemented the Delaware Court of Chancery's order enforcing the oral settlement agreement with Sarissa

LONDON & BRISBANE, Calif. --(BUSINESS WIRE)-- GlaxoSmithKline plc (LSE/ NYSE : GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing of a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) for the use of Trelegy Ellipta (fluticasone